Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aesculap Biologics, LLC
Subjects with articular knee defects will be randomized to receive either Microfracture or NOVOCART 3D. Subjects will be followed for five years in total and will be evaluated for safety and efficacy.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Greater than 18 years old
Isolated articular cartilage lesions on the femoral condyle 2-6 cm2
Minimum score on the KOOS questionnaire
You may not be if
Instability of the knee joint
Arthritis
Autoimmune disease
Immune suppression
Prior surgical treatment using mosaicplasty, autologous chondrocyte implantation and/or microfracture (debridement and lavage are acceptable beyond three months from baseline)
Bone disease
Any degenerative muscular, connective tissue or neurological condition or other disease process that would interfere with healing or the evaluation of outcome measures.
Clareo Health | NOVOCART®3D for Treatment of Articular Cartilage of the Knee
